Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA.Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Англійська |
| Опубліковано: |
2018
|
| Онлайн доступ: | https://doi.org/10.1136/annrheumdis-2017-211568 https://ard.bmj.com/content/annrheumdis/77/5/690.full.pdf |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|